Table 3.

Findings of Unadjusted and Adjusted Random Effects Models of the Effects of Obesity at Weeks 0, 24, or 48 on the Change in Levels of Inflammatory or Immune Activation Markers

Biomarker	Unadjusted Analysis		Adjusted Analysisa
	Slope (95% CI)	P Value	Slope (95% CI)	P Value
IL-6 level in pg/mL	−12.8 (−52.8 to 27.2)	.53	−23.4 (−65.2 to 18.4)	.27
TNF-α level in pg/mL	−1.3 (−6.2 to 3.5)	.60	−1.6 (−6.5 to 3.3)	.52
IFN-γ level in pg/mL	−1.5 (−19.8 to 16.7)	.87	4.8 (−12.9 to 22.5)	.59
CXCL-10 level in pg/mL	−57.8 (−593.0 to 477.4)	.83	−203.3 (−756.0 to 349.5)	.47
IL-18 level in pg/mL	131.0 (2.3–259.7)	.05	127.6 (−3.4 to 258.7)	.05
CRP level in mg/L	−5.7 (−17.7 to 6.3)	.35	−5.5 (−13.6 to 2.6)	.18
Log10 sCD14 level in pg/mL	0.2 (.05–.4)	.009	0.2 (.04–.4)	.02

Obesity was defined as a body mass index (calculated as the weight in kilograms divided by the height in meters squared) of >30.

Abbreviations: CI, confidence interval; CRP, C-reactive protein; CXCL-10, interferon γ–inducible protein 10; HIV, human immunodeficiency virus; IFN-γ, interferon γ; IL-6, interleukin 6; IL-18, interleukin 18; sCD14, soluble CD14; TNF-α, tumor necrosis factor α.

^a Adjusted for age, sex, country, study treatment arm, screening CD4⁺ T-cell count, baseline log₁₀ HIV RNA load, and prevalent tuberculosis.